Lessons from the ANTES B+ study
Lessons from the ANTES B+ study
About a year ago, Archivos de Bronconeumologia published the rationale, goals, design and methods of the ANTES B+ study [1], a pragmatic, prospective, randomized clinical trial whose primary objective was to investigate if treatment with inhaled triple therapy (LABA-LAMA-ICS) improved clinical control [2] during 12 months follow-up vs. the GOLD recommended dual therapy (LABA-LAMA) in a specific subgroup of GOLD B patients that we named B+ [3].
These B+ patients were characterized by having a CAT score >10 despite treatment with LABA-LAMA and having had a moderate exacerbation (treated with oral corticosteroids and/or antibiotics but not needing hospitalization) the year before and having more than 150 eosinophils/μL of circulating blood [1].
Scientific rationale and background
These inclusion criteria were based on previous observations that showed that: (1) patients who remain symptomatic (CAT >10) despite treatment with LABA-LAMA are at higher risk of worse health outcomes [3]; (2) GOLD B patients with 1 previous moderate exacerbation the year before had substantially higher hazard ratio of future exacerbation, all-cause hospitalization and respiratory hospitalization than those without them [4]; and (3) that higher level of circulating eosinophils identifies patients with a higher risk of future ECOPD, a better preventive response to inhaled corticosteroids (ICS), and reduced risk of ICS-related pneumonia [5].
Indeed, this hypothesis was proposed before the Global Initiative for Chronic Obstructive Lung Disease (GOLD) suggested in the 2026 GOLD recommendations to consider one moderate exacerbation enough to move the patient to the GOLD E group [6].
Finally, but importantly, this was going to be the first clinical trial with a composite outcome (clinical control) as the main endpoint. The concept of disease activity, disease stability and clinical control has also been highlighted in GOLD 2026 for the first time.
Finally, but importantly, this was going to be the first clinical trial with a composite outcome (clinical control) as the main endpoint. The concept of disease activity, disease stability and clinical control has also been highlighted in GOLD 2026 for the first time.
Recruitment and premature termination of the study
After obtaining all the necessary ethical approvals, recruitment of patients started in 2024. Unfortunately, one year later, despite having involved almost 40 recruiting centers around Spain, we had been able to randomize in the study only 48 patients.
Given that the estimated sample size of the study was 1028 patients [1], this rate of recruitment would have required to prolong the study for several years, so it was agreed between the investigators and the sponsoring company to stop the trial.
Lessons learned from the ANTES B+ study
In this scientific letter we first want to address our responsibility to inform the scientific community that the ANTES B+ study has been cancelled prematurely and the reasons for that but, also importantly, we would like to share some lessons learned from it because we think they may be useful for the design of future COPD trials.
The first lesson is that double therapy works very well in alleviating symptoms in COPD because it was very difficult to find symptomatic patients on LABA-LAMA with CAT >10.
Finding COPD patients who are highly symptomatic (CAT >10) but infrequent exacerbators while on dual therapy proved to be very difficult, which is actually an important clinical observation in itself.
Implications for clinical practice and future trials
The second lesson learned relates to the difficulty in finding B patients with one moderate exacerbation the year before who were not already on triple therapy.
This is an example that, sometimes, clinical practice does not follow the available scientific evidence.
Finally, we regret that the ANTES B+ study had to be stopped prematurely for the reasons discussed above and could not, for the first time, test a composite outcome (clinical control [2,7]) as the main endpoint of the study [1], an approach that might have provided new and valuable insights into the level of disease stability achieved in these patients by triple therapy, as compared to dual treatment.
We hope that this important question can be addressed in future trials.
Authors
Alvar Agusti, Juan José Soler-Cataluña
Read more details at
Fecha de publicación
Available online 5 January 2026
Categorías asociadas al artículo
Noticias relacionadas
Patients with COPD prioritise chronic symptoms and functional impact as key outcomes in exacerbation trials
Patients with COPD prioritise chronic symptoms and functional impact as key outcomes in COPD exacerbation treatment trials.
The early-stage lung immune infiltrate in patients with Idiopathic Pulmonary Fibrosis differentiate stable and progressive disease
Early-stage lung immune infiltrate in idiopathic pulmonary fibrosis and its association with stable versus progressive disease in early IPF patients.
Bronchiectasis and treatable traits: the journey from concept to clinical practice
Review of the treatable traits approach in bronchiectasis, exploring phenotypes, endotypes, comorbidities, and its translation into clinical practice.
Jornada RespirAP sobre salud respiratoria
Participa en la Jornada RespirAP el 6 de mayo de 2026, un evento clave para impulsar un plan estratégico nacional en salud respiratoria. Formación, colaboración y acción.
Ocho investigadores del Clínic-IDIBAPS entre los más citados del mundo según Clarivate Analytics
Ocho investigadores del Clínic-IDIBAPS han sido reconocidos como Highly Cited Researchers 2025 por Clarivate Analytics, situándose entre los científicos más influyentes del mundo.
Diagnostic Metabolomic Profiling of COPD as Potential Biomarkers in Older and Younger Patients
Study identifies 10-metabolite panel distinguishing COPD from healthy subjects with ~90% accuracy, highlighting lipid metabolism dysregulation and offering new diagnostic insights.
Imagen desarrollada ChatGPT y Canva